Clinical assessment of Optivate®, a high-purity concentrate of factor VIII with von Willebrand factor, in the management of patients with haemophilia A

Factor VIII (FVIII) concentrates have revolutionized the treatment of patients with haemophilia A. Concerns over the transmission of viral infections through these products have been addressed through stringent, donor‐screening procedures and robust antiviral manufacturing steps. Bio Products Labora...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Haemophilia : the official journal of the World Federation of Hemophilia 2011-05, Vol.17 (3), p.456-462
Hauptverfasser:	DMOSZYNSKA, A., KULICZKOWSKI, K., HELLMANN, A., TRELINSKI, J., KLOCZKO, J., BAGLIN, T., HAY, C., O'SHAUGHNESSY, D., ZAWILSKA, K., MAKRIS, M., SHAIKH-ZAIDI, R., GASCOIGNE, E., DASH, C.
Format:	Artikel
Sprache:	eng
Schlagworte:	Adolescent Adult Aged Child Drug Combinations efficacy factor VIII Factor VIII - administration & dosage Factor VIII - adverse effects Factor VIII - therapeutic use haemophilia A Hemophilia A - drug therapy Hemorrhage - drug therapy Hemorrhage - prevention & control Hemostatics - administration & dosage Hemostatics - adverse effects Hemostatics - therapeutic use Humans Male Middle Aged Original ORIGINAL ARTICLE Paediatrics Outcome Assessment, Health Care plasma-derived concentrates safety von Willebrand Factor - administration & dosage von Willebrand Factor - adverse effects von Willebrand Factor - therapeutic use Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!